Cyto-Mine ® is the next-generation single cell analysis system that enables users to simplify, automate, and speed up their antibody discovery as well as cell line development workflows.

CYTO-102 is under clinical development by CytoImmune Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.

Short interest in ALTAMIRA THERAPUTICS LTD SHS PAR $0.002 NEW (NASDAQ:CYTO) decreased during the last reporting period, falling from 105.41K to 50.63K. This put 1.35% of the company's publicly ...

Winnipeg, December 17, 2024 – TheNewswire - Cytophage Technologies Ltd. ("Cytophage" or "the Company") (TSXV: CYTO; FSE: 70G) is pleased to announce a positive outcome from the first Canadian patient ...

Providing ultra-high-throughput screening of single cell assays and antibody-producing cells as well as the ability to sort them, Cyto-Mine is ready for use. Sphere Fluidics has now successfully ...

Cyto-Mine: single-cell-analysis technology reinventing therapeutic discovery Download PDF ADVERTISEMENT FEATURE Advertiser retains sole responsibility for the content of this article ...